Shares of Insmed tumbled as low as 36.8%, or $1.60, on 10 October after the Monmouth Junction, New Jersey-based firm revealed the US FDA plans to continue the clinical hold placed on the company's Phase III trials for Arikace (liposomal amikacin for inhalation) in cystic fibrosis patients with Pseudomonas lung infections.
Insmed said it has not yet received a response from the agency about the hold on its nontuberculous mycobacterial (NTM)...
Welcome to Scrip
Create an account to read this article
Already a subscriber?